Axel Hauschild
阿克塞尔·豪斯希尔德
MD
Professor and Head, Skin Cancer Research Program, Department of Dermatology皮肤科皮肤癌研究项目主任兼教授
👥Biography 个人简介
Professor Hauschild is a founding architect of BRAF-targeted therapy in melanoma, having co-led BREAK-3 (dabrafenib vs. DTIC) and the COMBI-d and COMBI-AD trials. His long-term follow-up data on dabrafenib/trametinib have defined the durability frontier for targeted therapy in BRAF-mutant melanoma.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Dabrafenib/Trametinib Adjuvant (COMBI-AD)
Co-led COMBI-AD, the first trial to establish adjuvant dabrafenib plus trametinib significantly reducing relapse risk in resected stage III BRAF V600–mutant melanoma, with 5-year landmark benefit.
BRAF Inhibitor Monotherapy (BREAK-3)
Served as PI on BREAK-3 establishing dabrafenib's superiority over dacarbazine, contributing to initial FDA approval of BRAF inhibitor monotherapy.
Representative Works 代表性著作
Dabrafenib as adjuvant therapy combined with trametinib in stage III BRAF-mutated melanoma (COMBI-AD): 5-year efficacy and safety results
The Lancet Oncology (2022)
Five-year COMBI-AD data showing sustained RFS benefit with a potential cure fraction in adjuvant targeted therapy.
Dabrafenib in BRAF-mutated metastatic melanoma: a multicenter, open-label, phase 3 trial
The Lancet (2012)
Pivotal BREAK-3 trial establishing dabrafenib as standard of care, replacing DTIC for BRAF V600E melanoma.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Sebastian Bauer
University Hospital Essen (Universitätsklinikum Essen)
Suzanne George
Dana-Farber Cancer Institute / Harvard Medical School
Marcia S. Brose
Sidney Kimmel Cancer Center, Thomas Jefferson University
Lori J. Wirth
Massachusetts General Hospital, Harvard Medical School
关注 阿克塞尔·豪斯希尔德 的研究动态
Follow Axel Hauschild's research updates
留下邮箱，当我们发布与 Axel Hauschild（University Hospital Schleswig-Holstein, Campus Kiel）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment